Targeting prostate cancer with compounds possessing dual activity as androgen receptor antagonists and HDAC6 inhibitors.
Jadhavar PS, Ramachandran SA, Riquelme E, Gupta A, Quinn KP, Shivakumar D, Ray S, Zende D, Nayak AK, Miglani SK, Sathe BD, Raja M, Farias O, Alfaro I, Belmar S, Guerrero J, Bernales S, Chakravarty S, Hung DT, Lindquist JN, Rai R.
Jadhavar PS, et al. Among authors: ray s.
Bioorg Med Chem Lett. 2016 Nov 1;26(21):5222-5228. doi: 10.1016/j.bmcl.2016.09.058. Epub 2016 Oct 4.
Bioorg Med Chem Lett. 2016.
PMID: 27717544